Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep302 | Clinical case reports - Pituitary/Adrenal | ECE2016

Hypophysitis as a complication of ipilimumab treatment

Svilias Ioannis , Cap Jan

Introduction: In the last few years new imunomodulatory drugs are used for the treatment of metastatic melanoma. One of these drugs is ipilimumab, a monoclonal antibody that activates the immune system by targeting CTLA-4 protein receptor. This monoclonal antibody is very effective but there is a higher risk of endocrinopathies like an adverse effect of treatment, mostly hypophysitis and hypothyroidism.Case: We present a 68-year-old patient with metastat...

ea0063ep16 | Adrenal and Neuroendocrine Tumours | ECE2019

Multiple endocrine neoplasia typu 2B – case report

Svilias Ioannis , Gabalec Filip , Cap Jan

Introduction: Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disorder with an estimated prevalence of 1 per 30,000 in the general population. MEN2 is subclassified into two distinct syndromes: types 2A (MEN2A) and 2B (MEN2B). MEN2A and 2B are inherited in an autosomal dominant pattern with very high penetrance. In both syndromes, there is an occurrence of multicentric tumour formation in all organs where the RET proto-oncogene is expressed.<p ...

ea0049ep1197 | Clinical case reports - Thyroid/Others | ECE2017

Where is the thyroxin disappearing?

Svilias Ioannis , Gabalec Filip , Cap Jan

Introduction: The most common cause of loss of adequate substitution on a stable dose of replacement therapy is noncompliance. Impaired absorption and weight gain are also possible. We present a rare case of renal loss of thyroxin in severe nephritic syndrome.Case report: We present a 46 year old female after total thyroidectomy for Graves-Basedow disease. From 2005 she was euthyroid on a stable dose of L-thyroxin (100 μg/day). On phy...

ea0035p932 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Cabergoline-induced pneumocephalus: an unusual complication of macroprolactinoma treatment

Svilias Ioannis , Gabalec Filip , Cap Jan

Prolactinomas are the most common hormonally active tumours of the pituitary. The treatment of choice is pharmacological. They are treated with cabergolin, which decreases the level of prolactin as well as the size of the tumour. Rarely, dangerous complications can arise after a quick reduction of the tumour’s size.Case presentation: Two men with macroprolactinomas were initially treated with cabergoline (Dostinex®) in a dose of 1 mg per week w...

ea0022p208 | Clinical case reports and clinical practice | ECE2010

A family with Von Hippel - Lindau disease (VHL)

Svilias Ioannis , Cap Jan , Vasatko Tomas

We present a family with Von Hippel - Lindau disease (VHL). First two brothers were diagnosed with pheochromocytoma, one of them consecutively in both adrenals in a 16-years’ interval. Then the daughter of one of these two men was diagnosed with pheochromocytoma in both adrenals and one extraadrenal tumour. Later the daughter of the second man was successfully operated for unilateral pheochromocytoma. No neurological signs were present, no other tumours found, and the ocu...

ea0073ep203 | Thyroid | ECE2021

A rare brain metastases of papillary thyroid cancer

Svilias Ioannis , Cap Jan , Gabalec Filip

IntroductionPapillary thyroid cancer (PTC) has generally good prognosis irrespective of lymph node metastases. The rate of survival in patients with distant metastases is variable, depending upon the site of metastases and radioiodine accumulation status. The median survival of patients with brain metastases is approximately one year.CaseWe present a 66 years old woman with a tumour triplicity (PTC, breast ca...

ea0037ep950 | Thyroid (non-cancer) | ECE2015

Radioiodine treatment of Graves' disease: dose–response analysis

Cepkova Jitka , Svilias Ioannis , Krcalova Eva , Horacek Jiri

Introduction: Despite more than 60 years’ experience with radioactive iodine 131I (RAI) treatment of Graves’ disease (GD) about the most appropriate dosing regime is still controversial. The objective of our research was to analyse the outcome of RAI therapy in our cohort of patients.Methods: Retrospectively, we analysed 603 patients with GD (500 women and 103 men, mean age 51.5±12.7 years) treated with RAI. According to recomme...

ea0035p278 | Clinical case reports Thyroid/Others | ECE2014

Giant mediastinal parathyroid cyst with hyperparathyroidism: a case report

Gabalec Filip , Svilias Ioannis , Hornychova Helena , Habal Petr , Cap Jan

Primary hyperparathyroidism (PHPT) is rarely caused by parathyroid adenoma with cystic degeneration, especially by the cyst localized in mediastinum. Both differential diagnosis of mediastinal cyst and management of the patient can be challenging.Case presentation: A 57 years old woman was transferred from district hospital where her urosepsis and nephrolithiasis had been treated successfully. A liquid collection in left hemithorax had also been found du...

ea0056ep20 | Adrenal and Neuroendocrine Tumours | ECE2018

Malignant sympathetic paraganglioma – case report

Svilias Ioannis , Zelinka Tomas , Krcalova Eva , Cap Jan

Introduction: Paragangliomas are rare neuroendocrine tumors that arise from the extraadrenal paraganglia. Sympathetic paragangliomas usually secrete catecholamines and are located in the sympathetic paravertebral ganglia of thorax, abdomen and pelvis.Case report: We present a 66 year old patient with an incidentally found retroperitoneal mass on spine MRI. An open biopsy was performed (9/15) with the histological finding of benign paraganglioma (accordin...

ea0022oc5.6 | Reproduction &amp; Thyroid | ECE2010

Universal screening detects twice more thyroid disorders in early pregnancy than targeted high-risk case finding

Horacek Jiri , Spitalnikova Sylvie , Dlabalova Blanka , Malirova Eva , Vizda Jaroslav , Svilias Ioannis , McGrath Catherine , Maly Jaroslav

Screening of thyroid disorders in pregnancy has been a matter of controversy. Recent recommendations favour targeted high-risk case finding though this approach may miss a significant number of those affected (Vaidya et al. JCEM 2007).Among 398 non-selected women in the 10th week of pregnancy, thyrotropin (IRMA) >3.5 mIU/l was found in 10.3%, free thyroxine (RIA) <10 pmol/l in 2% and thyroperoxidase antibodies (RIA) >50 IU/ml in...